Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia
| Autor: | Efrat Wolfovitz, J.Gerald Brook, Inbal Avisar |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
medicine.medical_specialty Statin Combination therapy medicine.drug_class Atorvastatin Hyperlipidemia Familial Combined Gastroenterology Combined hyperlipidemia chemistry.chemical_compound Pharmacotherapy Internal medicine Hyperlipidemia Internal Medicine medicine Humans Pyrroles cardiovascular diseases Lovastatin Prospective Studies Triglycerides Aged Hypolipidemic Agents Pravastatin medicine.diagnostic_test Cholesterol business.industry nutritional and metabolic diseases Cholesterol LDL Middle Aged medicine.disease Endocrinology Treatment Outcome chemistry Heptanoic Acids lipids (amino acids peptides and proteins) Drug Therapy Combination Female Bezafibrate Lipid profile business medicine.drug |
| Zdroj: | European journal of internal medicine. 19(3) |
| ISSN: | 1879-0828 |
| Popis: | Background Mixed hyperlipidemia is a common disorder characterized by elevated VLDL and LDL levels. Patients with this syndrome usually are in need of combination therapy, comprising a fibric acid derivate with a statin drug in order to achieve LDL and triglyceride target values. Atorvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor demonstrated to be effective in reducing both cholesterol (CHOL) and triglyceride (TG) levels in humans. We examined the efficacy of atorvastatin as monotherapy in achieving a better or the same lipid profile in patients with mixed hyperlipidemia treated with combination therapy. Design We compared atorvastatin with a combination of a fibric acid derivate and a statin drug (other than atorvastatin) in a 24-week, prospective randomized, open-label study of 27 patients with mixed hyperlipidemia. Methods All 27 patients had been treated with statin–fibrate therapy in different regimens for at least a year. Atorvastatin at a daily dose of 20 mg was substituted for statin–fibrate therapy. Lipid and safety profiles were assessed. Results Atorvastatin significantly reduced total cholesterol, LDL-C, and HDL-C compared to statin–fibrate therapy. In contrast, TG and glucose levels were significantly elevated with atorvastatin. Target LDL-C and TG was achieved in 10 patients with the single therapy of atorvastatin vs. 6 patients under statin–fibrate. In 16 patients, atorvastatin was at least as effective as, or better than, the combination therapy, and was recommended for continuation of treatment. Conclusion Atorvastatin is an adequate monotherapy for many mixed hyperlipidemia patients. We recommend atorvastatin be considered for every patient suffering from mixed hyperlipidemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect